ConductScience.org, home

Paper33337920

A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine.

Pellesi L and 8 others. Expert Opin Drug Saf, 2021. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Papers, record 33337920. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33337920

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine.
PubMed
Journal
Expert Opin Drug Saf
PubMed
Year
2021
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.55
iCite
Revised in PubMed
2021-04-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pellesi LLanfranco
2De Icco RRoberto
3Alawie HYHassan Youssef
4Andersen MMorten
5Liang DDavidhttps://orcid.org/0000-0002-7297-3042
6Amirguliyev SSarkhan
7Al-Karagholi MAMohammad Al-Mahdi
8Amin FMFaisal Mohammad
9Sessa MMauriziohttps://orcid.org/0000-0003-0874-4744

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Calcitonin Gene-Related Peptide Receptor AntagonistsMajor topic
Migraine DisordersMajor topic
Body Mass Index
Humans
Regression Analysis

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42201619CGRP-targeted therapies for migraine and the risk of infection.Intern Emerg Med2026https://conductscience.org/library/papers/42201619PubMed
40281424Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment.J Headache Pain2025https://conductscience.org/library/papers/40281424PubMed
36482037Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis.Clin Drug Investig2023https://conductscience.org/library/papers/36482037PubMed
34731334Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.Neurol Sci2022https://conductscience.org/library/papers/34731334PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33337920

GET https://conductscience.org/api/papers/v1/33337920/authors